Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.

ABSTRACT:

Introduction

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), a disease with a severe global burden. The intractability of Mtb has prevented the identification of clear correlates of protection against TB and hindered the development of novel TB vaccines that are urgently required. Lipid nanoparticle (LNP)-formulated mRNA is a highly promising vaccine platform that has yet to be thoroughly applied to TB.

Methods

We selected five Mtb antigens (PPE15, ESAT6, EspC, EsxI, MetE) and evaluated their potential as LNP-formulated mRNA vaccines, both when each antigen was delivered individually, and when all five antigens were combined in a mix regimen (m-Mix).

Results

Each mRNA construct demonstrated unique cellular and

SUBMITTER: De Voss CJ 

PROVIDER: S-EPMC11865049 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature